Vigonvita Life Sciences Co., Ltd. (02630.HK) Stock Price, Financials & Summary | drillr

Skip to content

Sign in Sign up

Price chart

Aug 6Aug 11Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

—

Market Cap

HKD 15.87B

MomentumView details →

1D Return

+0.05%

YTD Return

+15.98%

RSI (14)

51.3

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

—

Market Cap

HKD 15.87B

RSI (14)

51.3

MomentumView details →

1D Return

+0.05%

YTD Return

+15.98%

ProfitabilityView details →

Gross Margin

—

Net Margin

—

EBITDA Margin

—

ROE (TTM)

—

ROA (TTM)

—

Asset Turnover

—

GrowthView details →

Revenue YoY

—

EPS YoY

—

FCF YoY

—

Revenue CAGR 3Y

—

EPS CAGR 3Y

—

EBITDA YoY

—

EarningsView details →

EPS (Actual)

—

EPS Surprise

—

Beats (12Q)

—

Next Q EPS Est

—

Avg Surprise (4Q)

—

Rev Surprise

—

Capital & dividendView details →

Debt/Equity

—

Current Ratio

—

Quick Ratio

—

Div Yield

—

Div Rate

—

Div Growth 1Y

—

Financials snapshotView financials →

Revenue (TTM)

—

Net Income (TTM)

—

Op. CF (TTM)

—

Latest newsMore news →

Wangshan Wangshui-B (02630.HK) announced interim results for the six months ended June 2026, with revenue of RMB 132 million, up 693.7% year-on-year, and a narrowed loss of RMB 122 million versus a loss of RMB 173 million in the prior-year period.7d ago

Similar companies

通化东宝600867.SH Metacare Co., Ltd.118000.KS 奥瑞德600666.SH Tdspharm464280.KQ BCWORLD PHARM. Co., Ltd.200780.KQ Biogen Inc.BIIB Find similar companies →

Latest newsMore news →

Wangshan Wangshui-B (02630.HK) announced interim results for the six months ended June 2026, with revenue of RMB 132 million, up 693.7% year-on-year, and a narrowed loss of RMB 122 million versus a loss of RMB 173 million in the prior-year period.7d ago